Evidence map›Paper›PMID 33706794›Full record

ArticleBMC pharmacology & toxicology2021

Impact of previous exposure to systemic corticosteroids on unfavorable outcome in patients hospitalized for COVID-19.

Margaux Lafaurie, Guillaume Martin-Blondel, Pierre Delobel, Nassim Kamar, Sandrine Charpentier, Agnès Sommet, Guillaume Moulis, Covid-Clinic-Toul investigators

Open access · goldAbstract read
In one paragraph

Article in BMC pharmacology & toxicology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Repurposing of Chemotherapeutics to Combat COVID-19.Current topics in medicinal chemistry · 2022
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Margaux LafaurieService de Pharmacologie Médicale, Centre Hospitalier Universitaire de Toulouse, Faculté de Médecine, 37 allées Jules Guesde, 31000, Toulouse, France. margaux.lafaurie@univ-tlse3.fr.ORCID 0000-0001-6010-2891
Guillaume Martin-BlondelService des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse-Purpan, place du Dr Baylac, TSA40031, 31059, Toulouse, Cedex 9, France.
Pierre DelobelService des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse-Purpan, place du Dr Baylac, TSA40031, 31059, Toulouse, Cedex 9, France.
Nassim KamarService de Néphrologie et Transplantation d'Organes, Centre Hospitalier Universitaire de Toulouse-Rangueil, 1, avenue du Professeur Jean Poulhès - TSA 50032, 31059, Toulouse cedex 9, France.
Sandrine CharpentierService des Urgences, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
Agnès SommetService de Pharmacologie Médicale, Centre Hospitalier Universitaire de Toulouse, Faculté de Médecine, 37 allées Jules Guesde, 31000, Toulouse, France.
Guillaume MoulisCentre d'investigation clinique 1436, axe pharmacoépidémiologie, Centre Hospitalier Universitaire de Toulouse-Purpan, place du Dr Baylac, TSA40031, 31059, Toulouse, Cedex 9, France.
Covid-Clinic-Toul investigators
Centre Hospitalier Universitaire de Toulouse · FRCentre National de la Recherche Scientifique · FRUniversité Toulouse III - Paul Sabatier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe impact of prior exposure to systemic corticosteroids on COVID-19 severity in patients hospitalized for a SARS-CoV-2 pneumonia is not known. The present study was designed to answer to this question.

methodsThe population study was the Covid-Clinic-Toul cohort which records data about all hospitalized patients with a positive reverse transcriptase polymerase chain reaction for a SARS-CoV-2 infection at Toulouse University hospital, France. Exposure to systemic corticosteroids was assessed at hospital admission. A propensity score (PS) according to corticosteroid exposure was calculated including comorbidities, clinical, radiological and biological variables that impact COVID-19 severity. The primary outcome was composite, including admission to intensive care unit, need of mechanical ventilation and death occurring during the 14 days after hospital admission. Logistic regression models adjusted for the PS (overlap weighting) provided odds ratios (ORs) and their 95% confidence intervals (95% CIs).

resultsOverall, 253 patients were included in the study. Median age was 64 years, 140 patients (59.6%) were men and 218 (86.2%) had at least one comorbidity. Seventeen patients (6.7%) were exposed to corticosteroids before hospital admission. Chronic inflammatory disease (n = 8) was the most frequent indication. One hundred and twenty patients (47.4%) met the composite outcome. In the crude model, the OR of previous exposure to systemic corticosteroids was 1.64; 95% CI: 0.60-4.44. In the adjusted model, it was 1.09 (95% CI: 0.65-1.83).

conclusionOverall, this study provide some evidences for an absence of an increased risk of unfavorable outcome with previous exposure to corticosteroids in the general setting of patients hospitalized for COVID-19.

Indexed as

COVID-19 Drug TreatmentAdrenal Cortex HormonesAgedCohort StudiesComorbidityCOVID-19Critical CareFemaleHospitalizationHumansInflammationMaleMiddle AgedPropensity ScoreRespiration, ArtificialTreatment OutcomeAdrenal Cortex HormonesCOVID-19Intensive care unitMortalityPharmacoepidemiologySARS-COV-2Systemic corticosteroids

Identifiers

PMID33706794
PMCPMC7948656
OpenAlexW3134202204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.